M
Motoki Yoshida
Researcher at Osaka Medical College
Publications - 30
Citations - 1009
Motoki Yoshida is an academic researcher from Osaka Medical College. The author has contributed to research in topics: Oxaliplatin & Bevacizumab. The author has an hindex of 12, co-authored 29 publications receiving 896 citations.
Papers
More filters
Journal ArticleDOI
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms
Shin'ichi Miyamoto,Manabu Muto,Yasuo Hamamoto,Narikazu Boku,Atsushi Ohtsu,Satoshi Baba,Motoki Yoshida,Masana Ohkuwa,Hosokawa K,Hisao Tajiri,Shigeaki Yoshida +10 more
TL;DR: In this article, an insulated-tip electrosurgical knife (IT-EMR) was used for en bloc resection of intramucosal lesions in 120 patients with gastric neoplasms.
Journal ArticleDOI
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yasuhide Yamada,Daisuke Takahari,Hiroshi Matsumoto,Hideo Baba,Masato Nakamura,Kazuhiro Yoshida,Motoki Yoshida,Shigeyoshi Iwamoto,Ken Shimada,Yoshito Komatsu,Yasutsuna Sasaki,Taroh Satoh,Keiichi Takahashi,Hideyuki Mishima,Kei Muro,Masahiko Watanabe,Yuh Sakata,Satoshi Morita,Yasuhiro Shimada,Kenichi Sugihara +19 more
TL;DR: This trial aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) as first-line chemotherapy for metastatic colorectal cancer.
Journal ArticleDOI
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Kentaro Yamazaki,Michitaka Nagase,Hiroshi Tamagawa,Shinya Ueda,Takao Tamura,Kohei Murata,T. Eguchi Nakajima,Eishi Baba,Miho Tsuda,Toshikazu Moriwaki,Taito Esaki,Yasushi Tsuji,K. Muro,Koichi Taira,Tadamichi Denda,Sadao Funai,K. Shinozaki,Hideaki Yamashita,Naotoshi Sugimoto,Tatsuya Okuno,Tomohiro Nishina,M. Umeki,T. Kurimoto,Tetsuji Takayama,Akihito Tsuji,Motoki Yoshida,Ayumu Hosokawa,Yoshihiro Shibata,Koichi Suyama,Masataka Okabe,Kenji Suzuki,Nobuhiko Seki,Kentaro Kawakami,Michihiko Sato,Koshi Fujikawa,Tomonori Hirashima,Takaya Shimura,Keisei Taku,Toshio Otsuji,F. Tamura,Eiji Shinozaki,K. Nakashima,Hiroki Hara,Takahiro Tsushima,M. Ando,Satoshi Morita,Narikazu Boku,Ichinosuke Hyodo +47 more
TL;DR: FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus beVacIZumab, as the first-line systemic treatment for mCRC.
Journal ArticleDOI
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
Motoki Yoshida,Atsushi Ohtsu,Narikazu Boku,Yoshinori Miyata,Kuniaki Shirao,Yasuhiro Shimada,Ichinosuke Hyodo,Wasaburo Koizumi,Minoru Kurihara,Shigeaki Yoshida,Seiichiro Yamamoto +10 more
TL;DR: Investigating prognostic factors for patients with metastatic gastric cancer treated by chemotherapy demonstrated that better performance status, a small number of metastatic sites and macroscopically non-scirrhous type tumors are independent favorable factors for survival.
Journal ArticleDOI
S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
Motoki Yoshida,Megumi Ishiguro,K. Ikejiri,Izumi Mochizuki,Yoshihiko Nakamoto,Yusuke Kinugasa,Akinori Takagane,Takeshi Endo,Hiroharu Shinozaki,Yasumasa Takii,Hidetaka Mochizuki,Kenjiro Kotake,Shingo Kameoka,Keiichi Takahashi,Toshiaki Watanabe,Mamoru Watanabe,Narikazu Boku,Naohiro Tomita,Eiji Nakatani,Kenichi Sugihara +19 more
TL;DR: This phase III study is the first study in which demonstrated the efficacy of S-1, an oral fluoropyrimidine, as adjuvant chemotherapy for stage III colon cancer by confirming its noninferiority to UFT/LV in terms of disease-free survival.